Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Insulin is a vital medicine for patients with diabetes mellitus. Newer, more expensive insulin products and the lack of generic insulins in the United States have increased costs for patients and insurers. OBJECTIVE: To examine Medicaid payment trends for insulin products. Cost information is available for all 50 states and has been recorded since the 1990s. DESIGN, SETTING, AND PARTICIPANTS: A time-series analysis comparing reimbursements and prices. Using state- and national-level Medicaid data from 1991 to 2014, we identified all patients who used 1 or more of the 16 insulin products that were continuously available in the United States between 2006 and 2014. Insulin products were classified into rapid-acting and long-acting analogs, short-acting, intermediate, and premixed insulins based on American Diabetes Association Guidelines. MAIN OUTCOMES AND MEASURES: Inflation-adjusted payments made to pharmacies by Medicaid per 1 mL (100 IU) of insulin in 2014 US dollars. RESULTS: Since 1991, Medicaid reimbursement per unit (1 mL) of insulin dispensed has risen steadily. In the 1990s, Medicaid reimbursed pharmacies between $2.36 and $4.43 per unit. By 2014, reimbursement for short-acting insulins increased to $9.64 per unit; intermediate, $9.22; premixed, $14.79; and long-acting, $19.78. Medicaid reimbursement for rapid-acting insulin analogs rose to $19.81 per unit. The rate of increase in reimbursement was higher for insulins with patent protection ($0.20 per quarter) than without ($0.05 per quarter) (P<.001).Total Medicaid reimbursements peaked at $407.4 million dollars in quarter 2 of 2014. Total volume peaked at 29.9 million units in quarter 4 of 2005 and was 21.2 million units in quarter 2 of 2014. CONCLUSIONS AND RELEVANCE: Between 1991 and 2014, there was a near-exponential upward trend in Medicaid payments on a per-unit basis for a wide variety of insulin products regardless of formulation, duration of action, and whether the product was patented. Although reimbursements for newer, patent-protected insulin analogs increased at a faster rate than reimbursements for older insulins, payments increased for all products we examined. Our findings suggest a lack of price competition in the United States for this class of medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Why is there no generic insulin? Historical origins of a modern problem
Greene, J. A., & Riggs, K. R. (2015) · New England Journal of Medicine · doi:10.1056/nejmms1411398 · Cited by 81
Cited by
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
WOUTERS, O. J., KANAVOS, P. G., & McKEE, M. (2017) · The Milbank Quarterly · doi:10.1111/1468-0009.12279 · Cited by 287
Insulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
National trends in pediatric admissions for diabetic ketoacidosis, 2006–2016
Everett, E. M., Copeland, T. P., Moin, T., & Wisk, L. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab287 · Cited by 38
Metadata
- Authors
- Luo, J., Avorn, J., & Kesselheim, A. S.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2015-10-01
- Volume
- 175
- Issue
- 10
- Pages
- 1681
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W1916729748
- Cited by
- 48
- References
- 2
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.